Patents by Inventor Thomas Meitinger

Thomas Meitinger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9546994
    Abstract: The present invention relates to a method of identifying a predisposition for developing type 2 diabetes mellitus in a subject, said method comprising the step of assessing in a sample obtained from said subject the amount of one or more metabolite(s) selected from (a) a first group comprising the metabolites glycine, lysoPhosphatidylcholine acyl C18:2, lysoPhosphatidylcholine acyl C17:0, lysoPhosphatidylcholine acyl C18:0, lysoPhosphatidylcholine acyl C18:1, phosphatidylcholine acyl-alkyl C34:2, phosphatidylcholine acyl-alkyl C36:2, phosphatidylcholine acyl-alkyl C36:3 and isobaric metabolites having the same molecular mass as glycine, lysoPhosphatidylcholine acyl C18:2, lysoPhosphatidylcholine acyl C17:0, lysoPhosphatidylcholine acyl C18:0, lysoPhosphatidylcholine acyl C18:1, phosphatidylcholine acyl-alkyl C34:2, phosphatidylcholine acyl-alkyl C36:2 or phosphatidylcholine acyl-alkyl C36:3 but different chemical formula; and/or (b) a second group comprising the metabolite acetylcarnitine C2 and an isobaric m
    Type: Grant
    Filed: August 13, 2013
    Date of Patent: January 17, 2017
    Assignees: Helmholtz Zentrum Munchen-Deutsches Forschungszentrum fur Geseundheit und Umwelt (GmbH), Deutsche Diabetes-Forschungsgesellschaft e.V.—Trager des Deutschen Diabetes-Zentrums Dusseldorf, Eberhard Karls Universitat Tubingen, Medizinische Fakultat
    Inventors: Wolfgang Rathmann, Christian Herder, Thomas Illig, Jerzy Adamski, Rui Wang-Sattler, Zhongao Yu, H.-Erich Wichmann, Hans-Ulrich Haring, Michael Roden, Annette Peters, Christine Meisinger, Martin Hrabe De Angelis, Thomas Meitinger
  • Publication number: 20150204839
    Abstract: The present invention relates to a method of identifying a predisposition for developing type 2 diabetes mellitus in a subject, said method comprising the step of assessing in a sample obtained from said subject the amount of one or more metabolite(s) selected from (a) a first group comprising the metabolites glycine, lysoPhosphatidylcholine acyl C18:2, lysoPhosphatidylcholine acyl C17:0, lysoPhosphatidylcholine acyl C18:0, lysoPhosphatidylcholine acyl C18:1, phosphatidylcholine acyl-alkyl C34:2, phosphatidylcholine acyl-alkyl C36:2, phosphatidylcholine acyl-alkyl C36:3 and isobaric metabolites having the same molecular mass as glycine, lysoPhosphatidylcholine acyl C18:2, lysoPhosphatidylcholine acyl C17:0, lysoPhosphatidylcholine acyl C18:0, lysoPhosphatidylcholine acyl C18:1, phosphatidylcholine acyl-alkyl C34:2, phosphatidylcholine acyl-alkyl C36:2 or phosphatidylcholine acyl-alkyl C36:3 but different chemical formula; and/or (b) a second group comprising the metabolite acetylcarnitine C2 and an isobaric m
    Type: Application
    Filed: August 13, 2013
    Publication date: July 23, 2015
    Applicant: Helmholtz Zentrum Munchen
    Inventors: Wolfgang Rathmann, Christian Herder, Thomas Illig, Jerzy Adamski, Rui Wang-Sattler, Zhongao Yu, H.-Erich Wichmann, Hans-Ulrich Haring, Michael Roden, Annette Peters, Christine Meisinger, Martin Hrabe De Angelis, Thomas Meitinger
  • Patent number: 8586317
    Abstract: The present invention relates to methods of diagnosing hypophosphatemic disorders.
    Type: Grant
    Filed: April 11, 2011
    Date of Patent: November 19, 2013
    Assignees: Advanced Research & Technology Institute, Ludwig-Maximilians-Universitat Munchen Abeteilung Mediziniche Genetik
    Inventors: Michael Econs, Kenneth E. White, Tim Matthias Strom, Thomas Meitinger
  • Patent number: 8409809
    Abstract: The present invention refers to a newly discovered gene named KASPP for Kinase Associated with Parkinsonism with Pleiomorphic Pathology or alternatively named LRRK2 for Leucine-Rich Repeat Kinase 2, its production, biochemical characterization and use for the detection and treatment of neurodegenerative disorders, such as Parkinson disease (PD) including, without limitation, sporadic PD, Alzheimer disease (AD), amyotrophic lateral sclerosis (ALS), and other synucleinopathies and/or tauopathy as well as several polymorphisms and mutations in the KASPP/LRRK2 gene segregated with PD.
    Type: Grant
    Filed: August 26, 2011
    Date of Patent: April 2, 2013
    Assignees: Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH), Eberhard-Karls-Universitaet Tuebingen, Mayo Foundation For Medical Education and Research
    Inventors: Thomas Meitinger, Tim Matthias Strom, Saskia Biskup, Marius Ueffing, Elisabeth Kremmer, Christian Johannes Gloeckner, Thomas Gasser, Petra Herzig, Friedrich Asmus, Nadja Patenge, Alexander Zimprich, Matthew J. Farrer, Jennifer M. Kachergus, Sara J. Lincoln, Mary M. Hulihan, Zibigniew Wszolek, Ryan Uitti
  • Publication number: 20120064544
    Abstract: The present invention relates to methods of diagnosing hypophosphatemic disorders.
    Type: Application
    Filed: April 11, 2011
    Publication date: March 15, 2012
    Inventors: Michael Econs, Ken White, Tim Matthias Strom, Thomas Meitinger
  • Publication number: 20120035072
    Abstract: The present invention refers to a newly discovered gene named KASPP for Kinase Associated with Parkinsonism with Pleiomorphic Pathology or alternatively named LRRK2 for Leucine-Rich Repeat Kinase 2, its production, biochemical characterization and use for the detection and treatment of neurodegenerative disorders, such as Parkinson disease (PD) including, without limitation, sporadic PD, Alzheimer disease (AD), amyotrophic lateral sclerosis (ALS), and other synucleinopathies and/or tauopathy as well as several polymorphisms and mutations in the KASPP/LRRK2 gene segregated with PD.
    Type: Application
    Filed: August 26, 2011
    Publication date: February 9, 2012
    Applicants: Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt (GmbH, Mayo Foundation for Medical Education and Research, Eberhard Karls Universitaet Tuebingen
    Inventors: Thomas Meitinger, Tim Matthias Strom, Saskia Biskup, Marius Ueffing, Elisabeth Kremmer, Christian Johannes Gloeckner, Thomas Gasser, Petra (Leitner) Herzig, Friedrich Asmus, Nadja Patenge, Alexander Zimprich, Matthew J. Farrer, Jennifer M. Kachergus, Sara J. Lincoln, Mary M. Hulihan, Zibigniew Wszolek, Ryan Uitti
  • Patent number: 8029986
    Abstract: The present invention refers to a newly discovered gene named KASPP for Kinase Associated with Parkinsonism with Pleiomorphic Pathology or alternatively named LRRK2 for Leucine-Rich Repeat Kinase 2, its production, biochemical characterization and use for the detection and treatment of neurodegenerative disorders, such as Parkinson disease (PD) including, without limitation, sporadic PD, Alzheimer disease (AD), amyotrophic lateral sclerosis (ALS), and other synucleinopathies and/or tauopathy as well as several polymorphisms and mutations in the KASPP/LRRK2 gene segregated with PD.
    Type: Grant
    Filed: September 27, 2005
    Date of Patent: October 4, 2011
    Assignees: Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt(GmbH), Eberhard Karls Universitaet Tuebingen, Mayo Foundation for Medical Education and Research
    Inventors: Thomas Meitinger, Tim Matthias Strom, Saskia Biskup, Marius Ueffing, Elisabeth Kremmer, Christian Johannes Gloeckner, Thomas Gasser, Petra Herzig, Friedrich Asmus, Nadja Patenge, Alexander Zimprich, Matthew J. Farrer, Jennifer M. Kachergus, Sara J. Lincoln, Mary M. Hulihan, Zibigniew Wszolek, Ryan Uitti
  • Patent number: 7947810
    Abstract: The present invention relates to a kit for diagnosing a disorder comprising a reagent that detects FGF23 polypeptides and mutant FGF23 polypeptides.
    Type: Grant
    Filed: November 7, 2007
    Date of Patent: May 24, 2011
    Assignees: Advanced Research & Technology Institute, Ludwig-Maximilians-Universitat Munchen Abeteilung Mediziniche Genetik
    Inventors: Michael Econs, Ken White, Tim Matthias Strom, Thomas Meitinger
  • Publication number: 20100235933
    Abstract: The present invention refers to a newly discovered gene named KASPP for Kinase Associated with Parkinsonism with Pleiomorphic Pathology or alternatively named LRRK2 for Leucine-Rich Repeat Kinase 2, its production, biochemical characterization and use for the detection and treatment of neurodegenerative disorders, such as Parkinson disease (PD) including, without limitation, sporadic PD, Alzheimer disease (AD), amyotrophic lateral sclerosis (ALS), and other synucleinopathies and/or tauopathy as well as several polymorphisms and mutations in the KASPP/LRRK2 gene segregated with PD.
    Type: Application
    Filed: September 27, 2005
    Publication date: September 16, 2010
    Applicants: Mayo Clinic, GSF Forschungszentrum fuer umwelt und Gesundheit GmbH, Eberhard Karls Universitaet Tuebingen
    Inventors: Thomas Meitinger, Tim Matthias Strom, Saskia Biskup, Marius Ueffing, Elisabeth Kremmer, Christian Gloeckner, Thomas Gasser, Petra Leitner, Friedrich Asmus, Nadja Patenge, Alexander Zimprich, Matthew J. Farrer, Jennifer M. Kachergus, Sara J. Lincoln, Mary M. Hulihan, Zibigniew Wszolek, Ryan Uitti
  • Patent number: 7745406
    Abstract: The present invention relates to a kit for diagnosing a disorder comprising a reagent that detects FGF23 polypeptides and mutant FGF23 polypeptides.
    Type: Grant
    Filed: November 7, 2007
    Date of Patent: June 29, 2010
    Assignees: Advanced Research & Technology Institute, Ludwig-Maximilians-Universitat Munchen Abteilung Medizinische Genetik
    Inventors: Michael Econs, Ken White, Tim Matthias Strom, Thomas Meitinger
  • Publication number: 20090311792
    Abstract: The present invention relates to a kit for diagnosing a disorder comprising a reagent that detects FGF23 polypeptides and mutant FGF23 polypeptides.
    Type: Application
    Filed: November 7, 2007
    Publication date: December 17, 2009
    Inventors: Michael Econs, Ken White, Tim Matthias Strom, Thomas Meitinger
  • Patent number: 7607669
    Abstract: A split electromechanical motor vehicle stabilizer having a locking device, and a method for roll stabilization are described. A split motor vehicle stabilizer is provided for roll stabilization, having a built-in electromechanical actuator for bracing two stabilizer parts against one another, including at least an electric motor, a gear unit, and a locking device which can lock a housing for the actuator to a rotor in the electric motor. The housing is connected to one of the stabilizer parts, and a gear unit output shaft is connected to the other stabilizer part for the purpose of transmitting torque. The housing and the rotor can be locked in only one position relative to one another after the locking device is activated, and that is the normal position for the two halves of the stabilizer in which they are not braced against one another.
    Type: Grant
    Filed: September 21, 2007
    Date of Patent: October 27, 2009
    Assignee: Bayerische Motoren Werke Aktiengesellschaft
    Inventors: Timo Anderten, Thomas Meitinger
  • Publication number: 20080241946
    Abstract: The present invention relates to a kit for diagnosing a disorder comprising a reagent that detects FGF23 polypeptides and mutant FGF23 polypeptides.
    Type: Application
    Filed: November 7, 2007
    Publication date: October 2, 2008
    Inventors: Michael Econs, Ken White, Tim Matthias Strom, Thomas Meitinger
  • Publication number: 20080007023
    Abstract: A split electromechanical motor vehicle stabilizer having a locking device, and a method for roll stabilization are described. A split motor vehicle stabilizer is provided for roll stabilization, having a built-in electromechanical actuator for bracing two stabilizer parts against one another, including at least an electric motor, a gear unit, and a locking device which can lock a housing for the actuator to a rotor in the electric motor. The housing is connected to one of the stabilizer parts, and a gear unit output shaft is connected to the other stabilizer part for the purpose of transmitting torque. The housing and the rotor can be locked in only one position relative to one another after the locking device is activated, and that is the normal position for the two halves of the stabilizer in which they are not braced against one another.
    Type: Application
    Filed: September 21, 2007
    Publication date: January 10, 2008
    Applicant: Bayerische Motoren Werke Aktiengesellschaft
    Inventors: Timo Anderten, Thomas Meitinger
  • Patent number: 7314618
    Abstract: The present invention relates to antibodies that bind to FGF23 polypeptides and to FGF23 mutant polypeptides.
    Type: Grant
    Filed: March 4, 2003
    Date of Patent: January 1, 2008
    Assignees: Advanced Research and Technology Institute, Ludwig-Maximilians-Universtat Munchen
    Inventors: Michael Econs, Ken White, Tim Matthias Strom, Thomas Meitinger
  • Patent number: 7223563
    Abstract: The invention relates to novel nucleic acids encoding a fibroblast growth factor-23(FGF23) and proteins encoded thereby, mutations in which are associated with autosomal dominant rickets (ADHR). The invention further relates to methods of diagnosing and treating hypophosphatemic and hyperphosphatemic disorders comprising inhibiting or stimulating, respectively, the biological activity of FGF23 in a patient. The invention also relates to methods of treating osteoporosis, dermatomyositis, and coronary artery disease comprising stimulating the biological activity of FGF23 in a patient.
    Type: Grant
    Filed: July 10, 2001
    Date of Patent: May 29, 2007
    Assignees: Advanced Research and Technology Institute, Ludwig-Maximilians-Universitat Muchen
    Inventors: Michael Econs, Ken White, Tim Matthias Strom, Thomas Meitinger
  • Publication number: 20030181379
    Abstract: The invention relates to novel nucleic acids encoding a fibroblast growth factor-23(FGF23) and proteins encoded thereby, mutations in which are associated with autosomal dominant rickets (ADHR). The invention further relates to methods of diagnosing and treating hypophosphatemic and hyperphosphatemic disorders comprising inhibiting or stimulating, respectively, the biological activity of FGF23 in a patient. The invention also relates to methods of treating osteoporosis, dermatomyositis, and coronary artery disease comprising stimulating the biological activity of FGF23 in a patient.
    Type: Application
    Filed: March 4, 2003
    Publication date: September 25, 2003
    Applicant: Advanced Research & Technology Institute and Ludwig-Maximilians-Universitat Munchen
    Inventors: Michael Econs, Ken White, Tim Matthias Strom, Thomas Meitinger
  • Publication number: 20020156001
    Abstract: The invention relates to novel nucleic acids encoding a fibroblast growth factor-23(FGF23) and proteins encoded thereby, mutations in which are associated with autosomal dominant rickets (ADHR). The invention further relates to methods of diagnosing and treating hypophosphatemic and hyperphosphatemic disorders comprising inhibiting or stimulating, respectively, the biological activity of FGF23 in a patient. The invention also relates to methods of treating osteoporosis, dermatomyositis, and coronary artery disease comprising stimulating the biological activity of FGF23 in a patient.
    Type: Application
    Filed: July 10, 2001
    Publication date: October 24, 2002
    Applicant: Advanced Research & Technology Institute and Ludwig-Maximilians-Universitat Munchen
    Inventors: Michael Econs, Ken White, Tim Matthias Strom, Thomas Meitinger